Although combined
chemotherapy and
radiotherapy has produced significantly improved response and survival rates among
cancer patients, there is still a compelling need to establish the most effective way to deliver these agents. We hypothesize that the
radiosensitizing effect of a chemotherapeutic agent can be further enhanced if the
drug is delivered at an optimal concentration and is maintained in the
tumor for a prolonged period. Using a water-soluble poly(
L-glutamic acid)-conjugated
paclitaxel (
PG-TXL) as a model compound, we investigated whether
paclitaxel delivered by means of polymeric carrier could increase the
tumor's response to radiation. Mice bearing 8-mm syngeneic ovarian
carcinoma OCa-1
tumors implanted intramuscularly were treated with i.v. injected
PG-TXL alone or in combination with single doses of local radiation. The enhancement factors at 24 h interval, as measured by incremental
tumor growth delay compared with radiation alone, ranged from 2.48 to 4.28. The values varied as a function of radiation dose. The enhancement of radioresponse is also a function of time interval between injection of
PG-TXL and
tumor irradiation. The enhancement factor increased with decreasing interval, suggesting that radiation may in turn mediate the sensitivity of
tumor toward
PG-TXL. Thus, the mechanism of
PG-TXL's radiopotentiation activity is probably multifactorial. Remarkably, while combined radiation and TXL produced additive or even sub-additive interaction when radiation preceded TXL injection, combined radiation and
PG-TXL produced synergistic interaction in a mammary MCa-4
tumor model. Radiation significantly increased
tumor uptake of
PG-TXL, suggesting a potential role of radiation-modulated antitumor activity of polymeric drugs. Our data support a treatment strategy combining radiation and polymeric
chemotherapy that may have important clinical implications in terms of scheduling and optimization of the therapeutic ratio.